Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma.

Jafarnejad M, Sové RJ, Danilova L, Mirando AC, Zhang Y, Yarchoan M, Tran PT, Pandey NB, Fertig EJ, Popel AS.

NPJ Syst Biol Appl. 2019 Aug 16;5:29. doi: 10.1038/s41540-019-0107-2. eCollection 2019.


Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.

Kim J, Lima E Silva R, Shmueli RB, Mirando AC, Tzeng SY, Pandey NB, Ben-Akiva E, Popel AS, Campochiaro PA, Green JJ.

Acta Biomater. 2019 Jul 30. pii: S1742-7061(19)30543-4. doi: 10.1016/j.actbio.2019.07.054. [Epub ahead of print]


A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling.

Mirando AC, Shen J, Silva RLE, Chu Z, Sass NC, Lorenc VE, Green JJ, Campochiaro PA, Popel AS, Pandey NB.

JCI Insight. 2019 Feb 21;4(4). pii: 122043. doi: 10.1172/jci.insight.122043. eCollection 2019 Feb 21.


Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection.

Zhang Y, Bazzazi H, Lima E Silva R, Pandey NB, Green JJ, Campochiaro PA, Popel AS.

Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5266-5276. doi: 10.1167/iovs.17-23632.


Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.

Jin K, Pandey NB, Popel AS.

Breast Cancer Res. 2018 Jun 14;20(1):54. doi: 10.1186/s13058-018-0981-3.


Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells.

Bressler EM, Kim J, Shmueli RB, Mirando AC, Bazzazi H, Lee E, Popel AS, Pandey NB, Green JJ.

J Biomed Mater Res A. 2018 Jun;106(6):1753-1764. doi: 10.1002/jbm.a.36360. Epub 2018 Feb 23.


Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma.

Barbhuiya MA, Mirando AC, Simons BW, Lemtiri-Chlieh G, Green JJ, Popel AS, Pandey NB, Tran PT.

Oncotarget. 2017 Sep 21;8(60):101520-101534. doi: 10.18632/oncotarget.21148. eCollection 2017 Nov 24.


Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis.

Jin K, Pandey NB, Popel AS.

Oncotarget. 2017 Jul 21;8(36):60210-60222. doi: 10.18632/oncotarget.19417. eCollection 2017 Sep 1.


An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.

Norton KA, Wallace T, Pandey NB, Popel AS.

BMC Syst Biol. 2017 Jul 11;11(1):68. doi: 10.1186/s12918-017-0445-x.


Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.

Silva RLE, Kanan Y, Mirando AC, Kim J, Shmueli RB, Lorenc VE, Fortmann SD, Sciamanna J, Pandey NB, Green JJ, Popel AS, Campochiaro PA.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaai8030. doi: 10.1126/scitranslmed.aai8030.


Comparison of rapid bedside tests for phosphorylated insulin-like growth factor-binding protein 1 and fetal fibronectin to predict preterm birth.

Tripathi R, Tyagi S, Mala YM, Singh N, Pandey NB, Yadav P.

Int J Gynaecol Obstet. 2016 Oct;135(1):47-50. doi: 10.1016/j.ijgo.2016.03.030. Epub 2016 Jun 18.


Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes.

Fertig EJ, Lee E, Pandey NB, Popel AS.

Sci Rep. 2015 Jul 15;5:12133. doi: 10.1038/srep12133.


Heterogeneity of chemokine cell-surface receptor expression in triple-negative breast cancer.

Norton KA, Popel AS, Pandey NB.

Am J Cancer Res. 2015 Mar 15;5(4):1295-307. eCollection 2015.


Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.

Lee E, Pandey NB, Popel AS.

Expert Rev Mol Med. 2015 Jan 30;17:e3. doi: 10.1017/erm.2015.2. Review.


Inhibition of breast cancer growth and metastasis by a biomimetic peptide.

Lee E, Lee SJ, Koskimaki JE, Han Z, Pandey NB, Popel AS.

Sci Rep. 2014 Nov 20;4:7139. doi: 10.1038/srep07139.


A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.

Rosca EV, Penet MF, Mori N, Koskimaki JE, Lee E, Pandey NB, Bhujwalla ZM, Popel AS.

PLoS One. 2014 Nov 10;9(11):e111901. doi: 10.1371/journal.pone.0111901. eCollection 2014.


Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells.

Norton KA, Han Z, Popel AS, Pandey NB.

Onco Targets Ther. 2014 Sep 9;7:1571-82. doi: 10.2147/OTT.S65055. eCollection 2014.


Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis.

Lee E, Fertig EJ, Jin K, Sukumar S, Pandey NB, Popel AS.

Nat Commun. 2014 Sep 2;5:4715. doi: 10.1038/ncomms5715.


Lymphatic endothelial cells support tumor growth in breast cancer.

Lee E, Pandey NB, Popel AS.

Sci Rep. 2014 Jul 28;4:5853. doi: 10.1038/srep05853.


Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model.

Lee E, Pandey NB, Popel AS.

Clin Exp Metastasis. 2014 Jan;31(1):67-79. doi: 10.1007/s10585-013-9610-9. Epub 2013 Aug 21.


Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide.

Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS, Campochiaro PA, Green JJ.

Biomaterials. 2013 Oct;34(30):7544-51. doi: 10.1016/j.biomaterials.2013.06.044. Epub 2013 Jul 10.


Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors.

Koskimaki JE, Lee E, Chen W, Rivera CG, Rosca EV, Pandey NB, Popel AS.

Angiogenesis. 2013 Jan;16(1):159-70. doi: 10.1007/s10456-012-9308-7. Epub 2012 Sep 29.


Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth.

Koskimaki JE, Rosca EV, Rivera CG, Lee E, Chen W, Pandey NB, Popel AS.

Transl Oncol. 2012 Apr;5(2):92-7. Epub 2012 Apr 1.


Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides.

Rosca EV, Koskimaki JE, Pandey NB, Tamiz AP, Popel AS.

Chem Biol Drug Des. 2012 Jul;80(1):27-37. doi: 10.1111/j.1747-0285.2012.01376.x. Epub 2012 Apr 27.


Larazotide acetate promotes tight junction assembly in epithelial cells.

Gopalakrishnan S, Tripathi A, Tamiz AP, Alkan SS, Pandey NB.

Peptides. 2012 May;35(1):95-101. doi: 10.1016/j.peptides.2012.02.016. Epub 2012 Feb 28.


Larazotide acetate regulates epithelial tight junctions in vitro and in vivo.

Gopalakrishnan S, Durai M, Kitchens K, Tamiz AP, Somerville R, Ginski M, Paterson BM, Murray JA, Verdu EF, Alkan SS, Pandey NB.

Peptides. 2012 May;35(1):86-94. doi: 10.1016/j.peptides.2012.02.015. Epub 2012 Feb 27.


Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation.

Lee E, Rosca EV, Pandey NB, Popel AS.

Int J Biochem Cell Biol. 2011 Dec;43(12):1812-21. doi: 10.1016/j.biocel.2011.08.020. Epub 2011 Sep 6.


Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer.

Rosca EV, Koskimaki JE, Pandey NB, Wolff AC, Popel AS.

Cancer Biol Ther. 2011 Nov 1;12(9):808-17. doi: 10.4161/cbt.12.9.17677. Epub 2011 Nov 1.


Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity.

Rivera CG, Rosca EV, Pandey NB, Koskimaki JE, Bader JS, Popel AS.

J Med Chem. 2011 Oct 13;54(19):6492-500. doi: 10.1021/jm200114f. Epub 2011 Sep 13.


Anti-angiogenic peptides for cancer therapeutics.

Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS.

Curr Pharm Biotechnol. 2011 Aug;12(8):1101-16. Review.


Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

Lin R, Johnson SG, Connolly PJ, Wetter SK, Binnun E, Hughes TV, Murray WV, Pandey NB, Moreno-Mazza SJ, Adams M, Fuentes-Pesquera AR, Middleton SA.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2333-7. doi: 10.1016/j.bmcl.2009.02.067. Epub 2009 Feb 21.


Point mutations in the stem-loop at the 3' end of mouse histone mRNA reduce expression by reducing the efficiency of 3' end formation.

Pandey NB, Williams AS, Sun JH, Brown VD, Bond U, Marzluff WF.

Mol Cell Biol. 1994 Mar;14(3):1709-20.


Molecular modeling to predict the structural and biological effects of mutations in a highly conserved histone mRNA loop sequence.

Gabb HA, Harris ME, Pandey NB, Marzluff WF, Harvey SC.

J Biomol Struct Dyn. 1992 Jun;9(6):1119-30.


Different complexes are formed on the 3' end of histone mRNA with nuclear and polyribosomal proteins.

Pandey NB, Sun JH, Marzluff WF.

Nucleic Acids Res. 1991 Oct 25;19(20):5653-9.


Introns in histone genes alter the distribution of 3' ends.

Pandey NB, Chodchoy N, Liu TJ, Marzluff WF.

Nucleic Acids Res. 1990 Jun 11;18(11):3161-70.


A region in the coding sequence is required for high-level expression of murine histone H3 gene.

Hurt MM, Pandey NB, Marzluff WF.

Proc Natl Acad Sci U S A. 1989 Jun;86(12):4450-4.


Multiple regulatory steps control histone mRNA concentrations.

Marzluff WF, Pandey NB.

Trends Biochem Sci. 1988 Feb;13(2):49-52. Review. No abstract available.


Translation is required for regulation of histone mRNA degradation.

Graves RA, Pandey NB, Chodchoy N, Marzluff WF.

Cell. 1987 Feb 27;48(4):615-26.


Supplemental Content

Loading ...
Support Center